Exploring the role of botulinum toxin in critical care

References

• Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8):1131–1138.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Albanese A, Atassi MZ, et al. Botulinum toxin E-Book: therapeutic clinical practice and science. Elsevier Health Sci. 2009;1:XII-IV.
   Google Scholar
• Allergan. BOTOX (OnabolulinumtoxinA [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103000s5302lbl.pdf Revised [April/2017]. Accessed [2020 May 29].
   Google Scholar
• Solstice Neurosciences. Myobloc®(rimabotulinumtoxinB) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103846s5190lbl.pdf. Accessed [2020 May29].
   Google Scholar
• Pirazzini M, Rossetto O, Eleopra R, et al., Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017; 69(2): 459–463.
   PubMed Web of Science ®Google Scholar
• Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel). 2019;11(9):491.
   Web of Science ®Google Scholar
• Manji H, Howard R, Miller D, et al. Status dystonicus: the syndrome and its management. Brain. 1998;121(2):243–252.
   PubMedGoogle Scholar
• Lobato-Polo J, Ospina-Delgado D, Orrego-González E, et al. Deep brain stimulation surgery for status dystonicus: a single-center experience and literature review. World Neurosurg. 2018;114:e992–e1001.
   PubMed Web of Science ®Google Scholar
• Fasano A, Ricciardi L, Bentivoglio AR, et al. Status dystonicus: predictors of outcome and progression patterns of underlying disease. Mov Disord. 2012;27(6):783–788.
   PubMed Web of Science ®Google Scholar
• Mariotti P, Fasano A, Contarino MF, et al. Management of status dystonicus: our experience and review of the literature. Mov Disord. 2007;22(7):963–968.
   PubMed Web of Science ®Google Scholar
• Black KJ, Racette B, Perlmutter JS. Preventing contractions in neuroleptic malignant syndrome and dystonia. Am J Psychiatry. 1998;155(9):1298a–9.
   PubMed Web of Science ®Google Scholar
• Havaki-Kontaxaki BJ, Kontaxakis VP, Margariti MM, et al. Treatment of severe neuroleptic-induced tardive torticollis. Ann Gen Hosp Psychiatry. 2003;2(1):9.
   PubMedGoogle Scholar
• Fève A, Angelard B, Fé, et al. Postneuroleptic laryngeal dyskinesias: a cause of upper airway obstructive syndrome improved by local injections of botulinum toxin. Mov Disord. 1993;8(2):217–219.
   PubMed Web of Science ®Google Scholar
• Mameniškienė R, Wolf P. Epilepsia partialis continua: a review. Seizure. 2017 Jan;44:74–80.
   PubMed Web of Science ®Google Scholar
• Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006;21(9):1502.
   Web of Science ®Google Scholar
• Lee W-I, Carney PW, Hughes AJ, et al. Refractory focal motor seizures controlled with intramuscular botulinum toxin. Epilepsy Res. 2017;133:93–97.
   PubMed Web of Science ®Google Scholar
• Currà A, Trompetto C, Abbruzzese G, et al. Central effects of botulinum toxin type A: evidence and supposition. Mov Disord. 2004;19(S8):S60–4.
   PubMedGoogle Scholar
• Bedarf JR, Marek M, Bien CG, et al. Sustained effect of botulinum neurotoxin in myoclonus owing to epilepsia partialis continua. Mov Disord Clin Pract. 2015;2(4):402–406.
   PubMed Web of Science ®Google Scholar
• Kang JS, Krakow K, Roggendorf J, et al. Botulinum toxin treatment of epilepsia partialis continua. Mov Disord. 2009;24(1):141–143.
   PubMed Web of Science ®Google Scholar
• Lagueny A, Tison F, Burbaud P, et al. Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A. Mov Disord. 1999;14(1):182–185.
   PubMed Web of Science ®Google Scholar
• Lozsadi DA, Hart IK, Moore AP. Botulinum toxin A improves involuntary limb movements in Rasmussen syndrome. Neurology. 2004;62(7):1233–1234.
   PubMed Web of Science ®Google Scholar
• Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006;21(9):1500–1502.
   PubMed Web of Science ®Google Scholar
• Mader EC, Fisch BJ, Villemarette-Pittman NR, et al. Botulinum toxin injections for simple partial motor seizures associated with pain. Case Rep Med. 2012;2012:1–4.
   PubMedGoogle Scholar
• Wilkenfeld AJL, Frank SA, McCarthy DCJ. Botulinum Toxin for Painful Spasms From Focal Seizures: theoretical Considerations and Case Report. Neurologist. 2013;19(1):15–16.
   PubMed Web of Science ®Google Scholar
• Awaad Y, Tayem H, Elgamal A, et al. Treatment of childhood myoclonus with botulinum toxin type A. J Child Neurol. 1999;14(12):781–786.
   PubMed Web of Science ®Google Scholar
• Eisenschenk S, Gilmore R, Uthman B, et al. Botulinum toxin-induced paralysis of frontotemporal muscles improves seizure focus localization. Neurology. 2002;58(2):246–249.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Schachter SC. Botulinum toxin treatment is not effective for epilepsy partialis continua. Mov Disord. 1995;10(3):357–358.
   PubMed Web of Science ®Google Scholar
• Andrade L, Brucki SMD. Botulinum toxin A for trismus in cephalic tetanus. Arq Neuropsiquiatr. 1994;52(3):410–413.
   Google Scholar
• Santiago-Rosado LM, Lewison CS. Trismus. In: StatPearls [Internet]. StatPearls Publishing; 2019.http://www.ncbi.nlm.nih.gov/books/NBK493203/.AccessedMay20,2020 .
   Google Scholar
• Fietzek U, Kossmehl P, Barthels A, et al. Botulinum toxin B increases mouth opening in patients with spastic trismus. Eur J Neurol. 2009;16:1299–1304.
   PubMed Web of Science ®Google Scholar
• Dana MH, Cohen M, Morbize J, et al. Botulinum toxin for radiation-induced facial pain and trismus. Otolaryngology–Head and Neck Surgery. 2008;138(4):459–463.
   PubMed Web of Science ®Google Scholar
• Winterholler M, Heckmann J, Hecht M, et al. Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin. Neurology. 2002;58(3):502–503.
   PubMed Web of Science ®Google Scholar
• Giray E, Gencer-Atalay K, Karadağ-Saygı E, et al. The value of physiatrists in pediatric intensive care unit: a case report of botulinum toxin injection into masseter muscle for the treatment of trismus.
   Google Scholar
• Kobal F, Baqer A, Singaram JS. Botulinum Toxin A for spastic trismus due to brain stem encephalitis in a pediatric intensive care setting: a unique case report. Journal of pediatric intensive care. 2018;7(4):216–218.
   PubMed Web of Science ®Google Scholar
• Kadyan V, Clairmont AC, Engle M, et al. Severe trismus as a complication of cerebrovascular accident: a case report. Arch Phys Med Rehabil. 2005;86(3):594–595.
   PubMed Web of Science ®Google Scholar
• Restivo D, Maimone D, Patti F, et al. Trismus after stroke/TBI: botulinum toxin benefit and use pre-PEG placement. Neurology. 2005;64(12):2152–2153.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Simmons JH, Shahid MH, et al. Onabotulinum toxin-A injections for sleep bruxism: a double-blind, placebo-controlled study. Neurology. 2018;90(7):e559–e4.
   PubMed Web of Science ®Google Scholar
• Fougere RJ, Currie KD, Nigro MK, et al. Reduction in bladder-related autonomic dysreflexia after onabotulinumtoxina treatment in spinal cord injury. J Neurotrauma. 2016;33(18):1651–1657.
   PubMed Web of Science ®Google Scholar
• Gamé X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53:613–619.
   PubMed Web of Science ®Google Scholar
• Wan D, Krassioukov AV. Life-threatening outcomes associated with autonomic dysreflexia: a clinical review. J Spinal Cord Med. 2014;37(1):2–10.
   PubMed Web of Science ®Google Scholar
• Silver JR. Early autonomic dysreflexia. Spinal Cord. 2000;38(4):229–233.
   PubMed Web of Science ®Google Scholar
• Schurch B, Stöhrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–697.
   PubMed Web of Science ®Google Scholar
• Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):S60–S64.
   Web of Science ®Google Scholar
• Lockwood G, Durkee C, Groth T. Intravesical botulinum toxin for persistent autonomic dysreflexia in a pediatric patient. Case Rep Urol. 2016;2016:1–4.
   PubMedGoogle Scholar
• Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998;108(10):1435–1441.
   PubMed Web of Science ®Google Scholar
• Marie JP, Navarre I, Lerosey Y, et al. Bilateral laryngeal movement disorder and synkinesia: value of botulism toxin. Apropos of a case. Rev Laryngol Otol Rhinol (Bord). 1998;119:261–264.
   PubMedGoogle Scholar
• Goldstein R, Bright J, Jones SM, et al. Severe vocal cord dysfunction resistant to all current therapeutic interventions. Respir Med. 2007;101(4):182–188.
   Web of Science ®Google Scholar
• Merlo IM, Occhini A, Pacchetti C, et al. Not paralysis, but dystonia causes stridor in multiple system atrophy. Neurology. 2002;58(4):649–652.
   PubMed Web of Science ®Google Scholar
• Rai V, Goyal V, Shukla G, et al. Adductor laryngeal breathing dystonia in NBIA treated with botulinum toxin-A. Ann Indian Acad Neurol. 2013;16(3):409–410.
   PubMed Web of Science ®Google Scholar
• Altman KW, Mirza N, Ruiz C, et al. Paradoxical vocal fold motion: presentation and treatment options. Journal of Voice. 2000;14(1):99–103.
   PubMed Web of Science ®Google Scholar
• Ekbom DC, Garrett CG, Yung KC, et al. Botulinum toxin injections for new onset bilateral vocal fold motion impairment in adults. Laryngoscope. 2010;120(4):758–763.
   PubMed Web of Science ®Google Scholar
• Maillard I, Schweizer V, Broccard A, et al. Use of botulinum toxin type A to avoid tracheal intubation or tracheostomy in severe paradoxical vocal cord movement. Chest. 2000;118(3):874–876.
   PubMed Web of Science ®Google Scholar
• Myssiorek D. Recurrent laryngeal nerve paralysis: anatomy and etiology. Otolaryngol Clin North Am. 2004;37(1):25–44.
   PubMed Web of Science ®Google Scholar
• Koufman JA, Block C. Differential diagnosis of paradoxical vocal fold movement. Am J Speech Lang Pathol. 2008;17(4):327–334.
   PubMed Web of Science ®Google Scholar
• Sahin M, Aydogdu I, Akyildiz S, et al. Electromyography-guided botulinum toxin injection into the cricothyroid muscles in bilateral vocal fold abductor paralysis. Clin Exp Otorhinolaryngol. 2017;10(2):193–202.
   PubMed Web of Science ®Google Scholar
• Daniel SJ, Cardona I. Cricothyroid onabotulinum toxin a injection to avert tracheostomy in bilateral vocal fold paralysis. JAMA Otolaryngol Head Neck Surg. 2014;140(9):867–869.
   PubMed Web of Science ®Google Scholar
• Benninger MS, Hanick A, Hicks DM. Cricothyroid muscle botulinum toxin injection to improve airway for bilateral recurrent laryngeal nerve paralysis, a case series. J Voice. 2016;30(1):2–10.
   PubMedGoogle Scholar
• Zealear DL, Billante CR, Courey MS, et al. Electrically stimulated glottal opening combined with adductor muscle botox blockade restores both ventilation and voice in a patient with bilateral laryngeal paralysis. Ann Otol Rhinol Laryngol. 2002;111(6):500–506.
   PubMed Web of Science ®Google Scholar
• Waldron NH, Cooter M, Haney JC, et al. Temporary autonomic modulation with botulinum toxin type A to reduce atrial fibrillation after cardiac surgery. Heart Rhythm. 2019;16(2):178–184.
   PubMed Web of Science ®Google Scholar
• Romanov A, Pokushalov E, Ponomarev D, et al. Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: three-year follow-up of a randomized study. Heart Rhythm. 2019;16(2):172–177.
   PubMed Web of Science ®Google Scholar
• Gubbay A, Marie Blackmore A. Effects of salivary gland botulinum Toxin-A on drooling and respiratory morbidity in children with neurological dysfunction. Int J Pediatr Otorhinolaryngol. 2019;124:124–128.
   PubMed Web of Science ®Google Scholar
• Faria J, Harb J, Hilton A, et al. Salivary botulinum toxin injection may reduce aspiration pneumonia in neurologically impaired children. Int J Pediatr Otorhinolaryngol. 2015;79(12):2124–2128.
   PubMed Web of Science ®Google Scholar
• Raval TH, Elliott CA. Botulinum toxin injection to the salivary glands for the treatment of sialorrhea with chronic aspiration. Ann Otol Rhinol Laryngol. 2008;117(2):118–122.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee Y, Weiner D, et al. Botulinum toxin type a injections to salivary glands: combination with single event multilevel chemoneurolysis in 2 children with severe spastic quadriplegic cerebral palsy. Arch Phys Med Rehabil. 2006;87(1):141–144.
   PubMed Web of Science ®Google Scholar
• Isaacson SH, Ondo W, Jackson CE, et al. Safety and efficacy of rimabotulinumtoxinb for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol. 2020;77(4):461–469.
   PubMed Web of Science ®Google Scholar
• Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut. 2000;46(5):597–600.
   PubMed Web of Science ®Google Scholar
• Vanuytsel T, Bisschops R, Farré R, et al. Botulinum toxin reduces dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol. 2013;11(9):1115–1121.
   PubMed Web of Science ®Google Scholar
• Kim BW, Kim H-J, Hyun JK, et al. Botulinum toxin injection in the treatment of postextubation dysphagia: a case report. Ann Rehabil Med. 2018;42(2):358.
   PubMedGoogle Scholar
• Kim DY, Park C-I, Ohn SH, et al. Botulinum toxin type A for poststroke cricopharyngeal muscle dysfunction. Arch Phys Med Rehabil. 2006;87(10):758–763.
   Web of Science ®Google Scholar
• Masiero S, Briani C, Marchese-Ragona R, et al. Successful treatment of long-standing post-stroke dysphagia with botulinum toxin and rehabilitation. J Rehabil Med. 2006;38(3):201–203.
   PubMedGoogle Scholar
• De Grandis D, Faletti S, Pirali F, et al. Botulinum toxin treatment of severe dysphagia following brainstem stroke. World Journal of Neuroscience. 2013;3(4):275–281.
   Google Scholar
• Macht M, Wimbish T, Clark BJ, et al. Postextubation dysphagia is persistent and associated with poor outcomes in survivors of critical illness. Crit Care. 2011;15(5):R231.
   PubMed Web of Science ®Google Scholar
• Jeong S-H, Kim YJ, Kim YJ, et al. Endoscopic botulinum toxin injection for treatment of pharyngeal dysphagia in patients with cricopharyngeal dysfunction. Scand J Gastroenterol. 2018;53(10–11):1201–1205.
   PubMed Web of Science ®Google Scholar
• Wehrmann T, Schmitt TH, Arndt A, et al. Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction. Aliment Pharmacol Ther. 2000;14(11):1469–1477.
   PubMed Web of Science ®Google Scholar
• Gorelick A, Barnett J, Chey W, et al. Botulinum toxin injection after biliary sphincterotomy. Endoscopy. 2004;36(2):170–173.
   PubMed Web of Science ®Google Scholar
• Intiso D, Basciani M. Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury. J Rehabil Med. 2009;41(13):1100–1102.
   PubMed Web of Science ®Google Scholar
• Uchiyama A, Yamada K, Perera B, et al. Protective effect of botulinum toxin A after cutaneous ischemia-reperfusion injury. Sci Rep. 2015;5(1):9072.
   PubMedGoogle Scholar
• Yang W, Li G. The Safety and efficacy of botulinum toxin type A injection for postoperative scar prevention: a systematic review and meta-analysis. J Cosmet Dermatol. 2020;19(4):799–808.
   PubMed Web of Science ®Google Scholar
• Gassner HG, Brissett AE, Otley CC, et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006 8; 81(8): 1023–1028.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee SJ, Lee JW, et al. Clinical trial to evaluate the efficacy of botulinum toxin type A injection for reducing scars in patients with forehead laceration: a double-blinded, randomized controlled study. Medicine (Baltimore). 2019;98(34):e16952.
   PubMed Web of Science ®Google Scholar
• Zielinski MD, Kuntz M, Zhang X, et al. BOTULINUM TOXIN A INDUCED PARALYSIS OF THE LATERAL ABDOMINAL WALL AFTER DAMAGE CONTROL LAPAROTOMY: a MULTIINSTITUTIONAL, PROSPECTIVE, RANDOMIZED, PLACEBO CONTROLLED PILOT STUDY. J Trauma Acute Care Surg. 2016;80(2):237.
   PubMed Web of Science ®Google Scholar
• Cigna E, Maruccia M, Fanelli B, et al. Botulinum toxin type A in the healing of chronic lesion following bilateral spasticity of gluteus muscle. Int Wound J. 2014;11(4):412–415.
   PubMed Web of Science ®Google Scholar
• Ramirez‐Castaneda J, Jankovic J, Comella C, et al. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28(13):1775–1783.
   PubMed Web of Science ®Google Scholar
• Mashlah A, Farooq T, Khattar P, et al. Ruptured infective aortic aneurysm following esophageal botulinum toxin injection. Am J Clin Pathol. 2016;146(suppl_1). https://doi.org/10.1093/ajcp/aqw162.005.
   Google Scholar
• Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011;58(1):1–7.
   PubMed Web of Science ®Google Scholar
• Moon I, Chang S, Kim S. First case of anaphylaxis after botulinum toxin type A injection. Clin Exp Dermatol. 2017;42(7):760–762.
   PubMed Web of Science ®Google Scholar
• Coté TR, Mohan AK, Polder JA, et al., Botulinum toxin type A injections: adverse events reported to the US food and drug administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 53(3): 407–415. 2005.
   PubMed Web of Science ®Google Scholar
• Albavera-Hernández C, Rodríguez JM, Idrovo AJ. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil. 2009;23(5):394–407.
   PubMed Web of Science ®Google Scholar
• O’flaherty SJ, Janakan V, Morrow AM, et al. Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy. Dev Med Child Neurol. 2011;53(2):125–130.
   PubMed Web of Science ®Google Scholar
• Chertow DS, Tan ET, Maslanka SE, et al., Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 296(20): 2476–2479. 2006.
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry. 1997;62(2):198.
   PubMed Web of Science ®Google Scholar
• Coban A, Matur Z, Hanagasi HA, et al. Iatrogenic botulism after botulinum toxin type A injections. Clin Neuropharmacol. 2010;33(3):158–160.
   PubMed Web of Science ®Google Scholar
• Montastruc J, Marque P, Moulis F, et al. Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase. Dev Med Child Neurol. 2017;59(3):329–334.
   PubMed Web of Science ®Google Scholar
• Nong L, He W, Xu Y, et al. Severe respiratory failure after injection of botulinum toxin: case report and review of the literature. Zhonghua Jie He He Hu Xi Za Zhi= Zhonghua Jiehe He Huxi Zazhi= Chinese Journal of Tuberculosis and Respiratory Diseases. 2008;31:369–371.
   PubMedGoogle Scholar
• Crowner BE, Brunstrom JE, Racette BA. Iatrogenic botulism due to therapeutic botulinum toxin a injection in a pediatric patient. Clin Neuropharmacol. 2007;30(5):170–173.
   PubMed Web of Science ®Google Scholar
• Partikian A, Mitchell WG. Iatrogenic botulism in a child with spastic quadriparesis. J Child Neurol. 2007;22(10):1235–1237.
   PubMed Web of Science ®Google Scholar
• Rashid EAMA, El-Mahdy NM, Kharoub HS, et al. Iatrogenic botulism outbreak in egypt due to a counterfeit botulinum toxin a preparation - A descriptive series of patient features and outcome. Basic Clin Pharmacol Toxicol. 2018;123(5):622–627.
   PubMed Web of Science ®Google Scholar
• Fan K-L, Wang Y-L, Chu G, et al. Delayed antitoxin treatment of two adult patients with botulism after cosmetic injection of botulinum type A toxin. J Emerg Med. 2016;51(6):677–679.
   PubMed Web of Science ®Google Scholar
• Cangene Pharmaceutical BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] [package insert]. U.S. Food and Drug Administration website.https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/bat-botulism-antitoxin-heptavalent-b-c-d-e-f-g-equine. Accessed April 20, 2020.
   Google Scholar
• Young DL, Halstead LA. Pyridostigmine for reversal of severe sequelae from botulinum toxin injection. J Voice. 2014;28(6):830–834.
   PubMed Web of Science ®Google Scholar
• Boerner RM, Young DL, Gnagi SH, et al. Pyridostigmine for the reversal of severe adverse reactions to botulinum toxin in children. J Pediatr. 2018;194:241–243.
   PubMed Web of Science ®Google Scholar
• Davies JR, Liu SM, Acharya KR. Variations in the botulinum neurotoxin binding domain and the potential for novel therapeutics. Toxins (Basel). 2018;10(10):421.
   Web of Science ®Google Scholar
• Fonfria E, Maignel J, Lezmi S, et al. The expanding therapeutic utility of botulinum neurotoxins. Toxins (Basel). 2018;10(5):208.
   Web of Science ®Google Scholar